Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial

Journal:
The BMJ
Published:
Affiliations:
29
Authors:
30
Institutions Authors Share
Hengrui, China
3.000000
0.10
Cancer Institute and Hospital, CAMS & PUMC, China
2.000000
0.07
Henan Cancer Hospital, ZZU, China
1.000000
0.03
The First Hospital of Jilin University, China
1.000000
0.03
Tianjin Medical University Cancer Institute and Hospital, TMU, China
1.000000
0.03
The First Hospital of China Medical University, China
1.000000
0.03
Shandong Cancer Hospital, China
1.000000
0.03
Sun Yat-sen University Cancer Center (SYSUCC), SYSU, China
1.000000
0.03
Fourth Hospital of Hebei Medical University, China
1.000000
0.03
Cancer Center, WCSM/WCH SCH, China
1.000000
0.03
The First Affiliated Hospital of Guangxi Medical University, China
1.000000
0.03
Harbin Medical University Cancer Hospital, China
1.000000
0.03
Sun Yat-sen Memorial Hospital, SYSU, China
1.000000
0.03
Hospital and Cancer Center, CQU, China
1.000000
0.03
Tumor Hospital of Guangxi Medical University, China
1.000000
0.03
The First Affiliated Hospital, USTC, China
1.000000
0.03
Jilin Province Cancer Hospital, China
1.000000
0.03
Wuhan Union Hospital, HUST, China
1.000000
0.03
Zhejiang Cancer Hospital (ZJCH), China
1.000000
0.03
Cancer Hospital of Yunnan Province, China
1.000000
0.03
The First Affiliated Hospital of Xi'an Jiaotong University, XJTU, China
1.000000
0.03
Hubei Cancer Hospital (HBCH), China
1.000000
0.03
Cancer Hospital at The First Affiliated Hospital, Henan University of Science and Technology, China
1.000000
0.03
Beijing Cancer Hospital / School of Oncology, PKUHSC, China
1.000000
0.03
Nanfang Hospital, China
1.000000
0.03
Hunan Cancer Hospital, China
0.500000
0.02
Central South University (CSU), China
0.500000
0.02
Liaoning Cancer Hospital and Institute, China
0.500000
0.02
Dalian University of Technology (DUT), China
0.500000
0.02